Bariatric Surgery in Patients With Prader-Willi Syndrome
Abstract
Prader-Willi Syndrome (PWS) is a genetic disorder characterized by insatiable hyperphagia, resulting in severe, early-onset obesity that is often refractory to conventional management. The associated comorbidities and reduced life expectancy in PWS present a significant therapeutic challenge. This review synthesizes the existing literature on the controversial role, outcomes, and complexities of bariatric surgery in patients with PWS. In recent decades, bariatric surgical techniques have evolved from malabsorptive or restrictive operations to modern procedures such as sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). We present a 21-year-old male's SG case to illustrate key themes. Published series from specialized, high-volume centers demonstrate that SG and RYGB yield significant short- to mid-term weight loss and metabolic improvement with an acceptable perioperative risk profile. However, the fundamental challenge in PWS remains the persistent, inherent hyperphagia. As exemplified by the presented case and supported by the broader literature, this insatiable hunger severely limits long-term surgical success and frequently leads to substantial weight regain. Maintaining durable success requires rigorous, lifelong external dietary supervision and intensive multidisciplinary support. Moreover, ethical considerations, particularly regarding informed consent and procedural choice, complicate the application of bariatric surgery in this population. Bariatric surgery…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.